Daclizumab – Manipulating the immune system in unexpected ways
Daclizumab, marketed as Zinbryta, was approved for the treatment of relapsing-remitting multiple sclerosis (MS) in the USA and Europe in summer 2016. Daclizumab has shown […]
Biomedicine & Healthcare
multiple sclerosis